- Home
- GPCR vs CERT Comparison
GPCR vs CERT Comparison
Compare GPCR & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPCR
- CERT
- Stock Information
- Founded
- GPCR 2016
- CERT 2008
- Country
- GPCR United States
- CERT United States
- Employees
- GPCR N/A
- CERT N/A
- Industry
- GPCR
- CERT Retail: Computer Software & Peripheral Equipment
- Sector
- GPCR
- CERT Technology
- Exchange
- GPCR Nasdaq
- CERT Nasdaq
- Market Cap
- GPCR 1.8B
- CERT 1.6B
- IPO Year
- GPCR 2023
- CERT 2020
- Fundamental
- Price
- GPCR $34.17
- CERT $9.95
- Analyst Decision
- GPCR Buy
- CERT Buy
- Analyst Count
- GPCR 5
- CERT 7
- Target Price
- GPCR $86.80
- CERT $15.92
- AVG Volume (30 Days)
- GPCR 677.5K
- CERT 1.2M
- Earning Date
- GPCR 11-13-2024
- CERT 11-06-2024
- Dividend Yield
- GPCR N/A
- CERT N/A
- EPS Growth
- GPCR N/A
- CERT N/A
- EPS
- GPCR N/A
- CERT N/A
- Revenue
- GPCR N/A
- CERT $372,797,000.00
- Revenue This Year
- GPCR N/A
- CERT $10.39
- Revenue Next Year
- GPCR N/A
- CERT $10.57
- P/E Ratio
- GPCR N/A
- CERT N/A
- Revenue Growth
- GPCR N/A
- CERT 5.62
- 52 Week Low
- GPCR $26.61
- CERT $9.88
- 52 Week High
- GPCR $66.38
- CERT $19.87
- Technical
- Relative Strength Index (RSI)
- GPCR 35.81
- CERT 41.17
- Support Level
- GPCR $33.85
- CERT $10.54
- Resistance Level
- GPCR $38.48
- CERT $11.37
- Average True Range (ATR)
- GPCR 2.62
- CERT 0.39
- MACD
- GPCR -0.36
- CERT 0.03
- Stochastic Oscillator
- GPCR 3.67
- CERT 23.86
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.